Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis

Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03897192

Enrollment

Registered

2019-04-01

Start date

2018-10-01

Completion date

2019-03-20

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Punctate Inner Choroidopathy

Keywords

punctate inner choroidopathy, multifocal choroiditis, zonal outer retinopathy, long-term outcome

Brief summary

To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).

Interventions

DRUGBevacizumab

Anti-vascular endothelial growth factor (VEGF)

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR). * Follow up over 4 years.

Exclusion criteria

* Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) without zonal outer retinopathy (ZOR).

Design outcomes

Primary

Measure	Time frame	Description
Wilcoxon Signed-Rank test	Baseline, 4 year	A statistical comparison of average of different time point

Secondary

Measure	Time frame	Description
visual acuity	Baseline, 6 month, 12 month, 24 month, 36 month, 48 month	visual acuity change in logMAR in different time point

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026